October 17th, 2026The One Thing: Teaching, optic nerve regeneration, and retina trainees | Episode 2Himani Goyal, MD, John J. Chen, MD, PhD, and Mark P. Breazzano, MD, FACS, point to academic compensation, optic nerve damage, and who chooses retina.Read more
October 16th, 2026OT Roundup: Optogenetics Nobel Prize, BRUNELLO, DRAGON, eye transplantOT Roundup covers the optogenetics Nobel Prize, remigromig in DME with Veeral Sheth, MD, Stargardt disease and a total human eye transplant.Read more
October 14th, 2026The One Thing: What ophthalmologists aren’t talking about enough | Episode 1Timothy M. Janetos, MD, Donald J. D’Amico, MD, and Mark J. Gallardo, MD, point to uveitis access, clinical trial rigor, and procedural pharmaceuticals.Read more
October 12th, 2026AAO 2026: Tinlarebant in Stargardt disease: Jacque Duncan, MD, on DRAGON resultsJacque Duncan, MD, reviews phase 3 DRAGON data on oral tinlarebant for Stargardt disease and its mechanism-related visual effects.Read more
October 11th, 2026AAO 2026: MCO-010 sustains vision gains in RP through 4 yearsKenneth C. Fan, MD, MBA, shared 4-year REMAIN data showing durable vision gains with MCO-010 in retinitis pigmentosa.Read more
October 11th, 2026AAO 2026: Inside an ophthalmic medical mission to ArmeniaJohn A. Hovanesian, MD, discusses the Armenian Eyecare Project’s annual trip, from preparation and surgery to teaching and student involvement.Read more
October 11th, 2026AAO 2026: New trials target optic neuritis treatment questionsJohn J. Chen, MD, PhD, of Mayo Clinic discusses how NMOSD and MOGAD antibodies are changing optic neuritis care and the two trials now enrolling.Read more
October 19th, 2026Beyond slowing atrophy: Optogenetic therapy targets vision lost to GAJordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.Read more